 | SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program - PRNewswire
www.prnewswire.com - October 10 at 1:51 PM |
 | SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program
finance.yahoo.com - October 10 at 1:51 PM |
 | Analysts Anticipate SCYNEXIS Inc (NASDAQ:SCYX) to Announce -$0.22 Earnings Per Share
www.americanbankingnews.com - October 9 at 7:27 PM |
| SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris - PRNewswire
www.prnewswire.com - October 2 at 9:47 PM |
| SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
finance.yahoo.com - October 2 at 4:47 PM |
| Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet? - Yahoo Finance
finance.yahoo.com - October 1 at 4:30 PM |
| Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
finance.yahoo.com - October 1 at 4:30 PM |
 | Scynexis (SCYX) Reports Complete Last-Patient/Last-Visit Ahead of Schedule in 1st Ph. 3 Study (VANISH 303) of Oral Ibrexafungerp - StreetInsider.com
www.streetinsider.com - September 20 at 1:57 AM |
 | Scynexis up 11% on advancement of late-stage study of antifungal ibrexafungerp - Seeking Alpha
seekingalpha.com - September 20 at 1:57 AM |
| SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
finance.yahoo.com - September 20 at 1:57 AM |
| SCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - September 5 at 11:42 AM |
| SCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - September 4 at 9:47 AM |
| Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options - Yahoo Finance
finance.yahoo.com - August 22 at 9:08 AM |
 | Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options - Nasdaq
www.nasdaq.com - August 21 at 10:58 PM |
| Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options
finance.yahoo.com - August 21 at 10:58 PM |
| Brookline Capital Markets Starts SCYNEXIS (SCYX) at Buy - StreetInsider.com
www.streetinsider.com - August 19 at 8:10 PM |
| Scynexis: 2Q Earnings Snapshot - Yahoo Finance
finance.yahoo.com - August 9 at 8:36 AM |
| SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update - PRNewswire
www.prnewswire.com - August 7 at 11:16 PM |
| SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
finance.yahoo.com - August 7 at 11:16 PM |
| Scynexis (SCYX) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 7 at 11:16 PM |
| Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo Finance
finance.yahoo.com - August 2 at 12:56 AM |
| Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 2 at 12:56 AM |
| Aegis Capital Starts SCYNEXIS (SCYX) at Buy - StreetInsider.com
www.streetinsider.com - August 1 at 12:01 AM |
| SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference - Yahoo Finance
finance.yahoo.com - July 31 at 9:11 AM |
| SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
finance.yahoo.com - July 31 at 9:11 AM |
| What Scynexis' Trial Protocol News Says About Its Market Estimate - Seeking Alpha
seekingalpha.com - July 26 at 7:47 AM |
| SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study) - PRNewswire
www.prnewswire.com - July 24 at 8:26 AM |
| SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
finance.yahoo.com - July 24 at 8:26 AM |
| Key Takeaways From A Follow-Up Phone Call With Scynexis CEO - Seeking Alpha
seekingalpha.com - July 20 at 8:45 AM |
| Scynexis: Updates To Thesis, Expecting Rebound In The Near Term - Seeking Alpha
seekingalpha.com - July 4 at 6:59 PM |
| World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019 - PRNewswire
www.prnewswire.com - June 27 at 8:29 AM |
| World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
finance.yahoo.com - June 25 at 11:53 AM |
| Imagine Owning SCYNEXIS (NASDAQ:SCYX) And Trying To Stomach The 84% Share Price Drop - Yahoo Finance
finance.yahoo.com - June 19 at 8:02 PM |
| Imagine Owning SCYNEXIS (NASDAQ:SCYX) And Trying To Stomach The 84% Share Price Drop
finance.yahoo.com - June 19 at 8:02 PM |
| Scynexis And The Fungal Economy - Seeking Alpha
seekingalpha.com - June 17 at 8:09 PM |
| SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development - PRNewswire
www.prnewswire.com - June 14 at 8:38 AM |
| SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
finance.yahoo.com - June 14 at 8:38 AM |
| SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections
finance.yahoo.com - June 5 at 7:00 PM |
| SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp - PRNewswire
www.prnewswire.com - May 30 at 6:46 PM |
| SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
finance.yahoo.com - May 30 at 6:46 PM |
| Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 10 at 8:20 AM |
| Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 9 at 8:16 AM |
| SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update - PRNewswire
www.prnewswire.com - May 8 at 7:40 PM |
| Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
finance.yahoo.com - May 8 at 8:19 AM |
| Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq
www.nasdaq.com - May 7 at 7:04 PM |
| Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - May 7 at 7:04 PM |
| SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC) - PRNewswire
www.prnewswire.com - May 6 at 7:43 PM |
| SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
finance.yahoo.com - May 6 at 7:43 PM |
| SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) - PRNewswire
www.prnewswire.com - May 2 at 8:21 AM |
| SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) - Yahoo Finance
finance.yahoo.com - May 1 at 7:31 PM |
